DexCom — Jul 30, 2026 release

“This quarter’s performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan.” 2026 Annual Guidance Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance and increasing fiscal year 2026 guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels: • Revenue of $5.18 - $5.25 billion (approximately 11-13% growth) • Non-GAAP Gross Profit Margin of approximately 64% • Non-GAAP Operating Margin of approximately 23.5-24% • Adjusted EBITDA Margin of approximately 31.5-32% Second Quarter 2026 Financial Results Revenue: In the second quarter of 2026, worldwide revenue grew 13% to $1.308 billion on a reported basis, up from $1.157 billion in the second quarter of 2025. Gross Profit: GAAP gross profit totaled $830.0 million or 63.4% of revenue for the second quarter of 2026, compared to $688.8 million or 59.5% of revenue in the second quarter of 2025. Non-GAAP gross profit* totaled $838.5 million or 64.1% of reported revenue for the second quarter of 2026, compared to $695.9 million or 60.1% of reported revenue in the second quarter of 2025. Operating Income: GAAP operating income for the second quarter of 2026 was $318.3 million or 24.3% of revenue, compared to GAAP operating income of $212.6 million or 18.4% of revenue for the second quarter of 2025. 1 Second quarter 2026 organic revenue was $1.298 billion and excludes $9.9 million of foreign exchange impact and $0.2 million of acquired non-CGM revenue. Non-GAAP operating income* for the second quarter of 2026 was $328.3 million or 25.1% of reported revenue, compared to non-GAAP operating income of $221.8 million or 19.2% of reported revenue for the